Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07666009

Prevention of Rebound Pain After Orthopaedic Surgery With Peripheral Nerve Block (REBOUND)_part B

Rebound pain after peripheral nerve blocks reduces the benefits of regional anesthesia and increases opioid consumption. This rebound pain most likely results from suboptimal pain management, as patients receiving a peripheral nerve block are typically not given scheduled opioid doses. Oral Patient Controlled Analgesia (PCA) consists of an oral morphine prescription that allows patients to self-administer doses based on their pain score.

This study will compare patients undergoing elective orthopaedic surgery under general anaesthesia or sedation with a peripheral nerve block, receiving oral morphine PCA either with or without additional scheduled oral morphine doses.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

This study contains two parts, one for the upper limb and one for the lower limb. Each part will be published independently.

This registration concerns the lower limb cohort.

Patients from each cohort (upper limb and lower limb) will be randomized into two groups of 25 patients each, for a total enrollment plan of 50 patients per cohort. After written informed consent, patients will be allocated to one of the two groups according to a computer-generated randomization list.

In the control group, morphine will be administered exclusively on demand via oral PCA,based on pain intensity assessed using a numeric rating scale (VAS > 4). For oral PCA, one10 mg morphine tablet is placed on the patient's bedside table by the nursing staff. When the patients experience pain, they may take the tablet autonomously and subsequently inform the nurse, who then prepares and places a new tablet at bedside for the next potential pain episode. No scheduled or prophylactic opioid administration will be provided in this group. The maximal allowed dose through oral PCA will be 6 tablets (10mg each) per 24-hour period.

In the intervention group, morphine will be administered at predefined regular intervals, starting immediately in the postoperative period in addition to the availability of oral PCA morphine as mentioned above. Scheduled doses of 20mg slow-release oral morphine will be given at fixed 12 hour intervals. Patients will therefore receive regular morphine to ensure continuous baseline analgesia while still having access to an additional tablet via oral PCA in case of breakthrough pain, following the same nursing procedure as in the control group.

In both groups, standardized multimodal analgesia will be provided

The primary objective of this study is to assess and compare the highest pain score within the first 24 postoperative hours between the two groups using the Visual Analog Scale (VAS). The secondary objective is to assess the effect of the intervention on postoperative pain and analgesic outcomes, including morphine consumption, pain scores, need for additional nerve blocks, incidence of chronic pain, duration of analgesia, postoperative side effects, complications, and hospital length of stay.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients scheduled for elective orthopaedic surgery on the upper limb
  • Patients scheduled for elective orthopaedic surgery on the lower limb.
  • Score ASA I-III; Patients aged over 18 years; Signed informed consent.
  • Surgery under general anaesthesia or under sedation

Exclusion criteria

  • Refusal or inability to understand the informed consent
  • Allergy to any of the following medications: ropivacaine, paracetamol, ibuprofen, ketorolac, morphine,sufentanil, ondansetron, or dexamethasone
  • Patients with long term opioid treatment
  • Bleeding diathesis
  • Neurological disorders of the operated limb
  • Known renal insufficiency (eGFR <30 mL/min)
  • Known hepatic insufficiency (Child-Pugh class B or C);
  • Pregnant or breastfeeding women;
  • Alcohol dependence syndrome;
  • Patients under spinal anaesthesia;
  • Patients undergoing amputation procedures

Treatment and study plan

Morphine provided via oral PCA

Drug

Morphine will be administered according to a scheduled regimen (20mg slow release oral morphine at fixed 12-hour intervals), with additional oral PCA on demand for breakthrough pain (VAS > 4), following the same bedside tablet procedure as in the control group. The maximum allowed dose through oral PCA will be 6 tablets (10mg each) per 24-hour period.

Morphine provided via oral PCA + morphine administered at a scheduled regimen

Drug

morphine will be administered according to a scheduled regimen (20mg slow-release oral morphine at fixed 12-hour intervals), with additional oral PCA on demand for breakthrough pain (VAS > 4), following the same bedside tablet procedure as in the control group. The maximum allowed dose through oral PCA will be 6 tablets (10mg each) per 24-hour period.

Primary outcomes

  1. Worst pain score during the first 24 hours after surgery

    Time frame: 24 hours postoperatively

    Highest postoperative pain score during the first 24 hours after surgery, measured using a 0-10 Visual Analog Scale (VAS), where 0 indicates no pain and 10 indicates the worst pain imaginable

Secondary outcomes

  1. Minimal pain score during the first 12 hours after surgery

    Time frame: 12 hours postoperatively

    Lowest postoperative pain score during the first 12 hours after surgery, measured using a 0-10 Visual Analog Scale (VAS), where 0 indicates no pain and 10 indicates the worst pain imaginable

  2. Rebound pain score measured using the Visual Analog Scale (VAS)

    Time frame: From surgery until 24 hours postoperatively

    Rebound pain score calculated as the difference between the highest postoperative pain score within the first 24 hours after surgery and the lowest postoperative pain score within the first 12 hours after surgery. Pain intensity is assessed using a Visual Analog Scale (VAS) ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst pain imaginable. Higher rebound pain scores indicate greater pain rebound

  3. Rest and dynamic pain scores

    Time frame: At 2, 12, 24, 36, 48, 60, and 72 hours after surgery

    Rest and dynamic pain scores, measured using a 0-10 Visual Analogue Score (VAS), where 0 indicates no pain and 10 indicates the worst pain imaginable

  4. Incidence of severe pain

    Time frame: From surgery through 3 months after surgery

    Pain evaluated at >7/10, measured using a 0-10 Visual Analog Scale (VAS), where 0 indicates no pain and 10 indicates the worst pain imaginable

  5. Persistence of pain

    Time frame: During the follow-up period from discharge till 4 weeks and 3 months

    Incidence of persistent pain at 4 weeks and chronic pain at 3 months

  6. Morphine consumption in the recovery room

    Time frame: from admission until discharge from the recovery room, up to 2 hours

    consumption in mg

  7. PCA administered morphine consumption at day 1, 2 and 3

    Time frame: Day 1, 2 and 3 postoperatively

    Consumption in mg administered by PCA

  8. Total administered morphine consumption at day 1, 2, and 3

    Time frame: Day 1, 2 and 3 postoperatively

    Total consumption in mg

  9. Incidence of postoperative nausea and vomiting

    Time frame: At 2 hours, day 1, day 2 and day 3 postoperatively

    Presence of nausea or vomiting in the postoperative period

  10. Incidence of pruritus

    Time frame: At 2 hours, day 1, day 2 and day 3 postoperatively

    Presence of pruritus in the postoperative period

  11. Incidence of urinary retention requiring bladder catheterisation

    Time frame: At 2 hours, day 1, day 2 and day 3 postoperatively

    Urinary retention requiring catheterisation

  12. Hospital length of stay

    Time frame: At hospital discharge (typically within 5 days, according to our hospital's standard practice)

    Duration of hospitalization, measured as the number of days from surgery (baseline) to hospital discharge. Higher values indicate longer hospital stays.

  13. Requirement for a new peripheral nerve block

    Time frame: On postoperative day 1, 2 and 3

    Requirement for a new peripheral nerve block

  14. Duration of analgesia

    Time frame: From the time the block is performed up to 36 hours after surgery

    Time between block performance and the first dose of morphine

Study contacts

Contact information is provided by the study sponsor or research team.

Eric Albrecht, Prof.

CONTACT

[email protected]

+41 79 556 63 41

Iliana Mrazek

CONTACT

[email protected]

+41 79 556 85 06

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire Vaudois

Other

Registry information

Official study title

Prevention of Rebound Pain After Orthopaedic Surgery With Peripheral Nerve Block: a Single-blinded Randomised Controlled Trial

Acronym: REBOUND

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jun 24, 2026
Registry last updated
Jun 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.